Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults

The study is a randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mtb vaccine when administered intramuscularly (IM) on a 0,1-month schedule to adolescents and adults. This trial will be conducted in 3 cohorts: Interferon gamma release assay (IGRA)-positive Cohort, IGRA-Negative Cohort and Human Immunodeficiency virus (HIV) Cohort.

Inclusion criteria: * Capable of giving informed consent or informed assent (as appropriate). For participants below the age of consent, the participant's parent, or legally authorized representative (LAR) will be required to sign a statement of informed consent, in addition to the minor's signed statement of assent. * In the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of diary cards as applicable, and return for follow-up visits). * Agree to actively stay in contact with the trial site for the duration of the trial for the participants own safety. * Agree to provide updated contact information as necessary, and have no current plans to relocate from the trial area for the duration of the trial. * Healthy, or with preexisting stable disease, as established by medical history and physical examination and as determined by the investigator. * Negative sputum Xpert Ultra or similar assay result at screening. * Both males and females are included. Females are included with restrictions. Females must either be of non-childbearing potential, defined as pre-menarche, have a history of either current tubal ligation, hysterectomy, or ovariectomy, or post-menopause, or, if she is of childbearing potential, she has practiced abstinence from penile-vaginal intercourse or adequate contraception for 28 days prior to vaccination, has a negative pregnancy test on the day of screening and the day of first vaccination, and agrees to continue abstinence or adequate contraception until 2 months after the second dose of trial intervention. * HIV-negative test result at screening (IGRA-Positive Cohort and IGRA-Negative Cohort only). * HIV Cohort only: Participants with documented HIV infection who fulfill all of the following criteria: 1. Have reactive anti-HIV antibody at screening. 2. Have been on antiretroviral therapy (ART) for at least 3 consecutive months at screening and agree to remain on ART throughout the trial. 3. Have documented HIV Ribonucleic acid (RNA) \